InvaGen Pharmaceuticals, Inc. – FDA 483, Sep 19, 2023
Invagen Pharmaceuticals, Inc. in Central Islip, NY, a drug manufacturer, was cited for five observations during an FDA inspection. The findings indicate significant deficiencies in quality control unit oversight, including unreviewed GMP documents, lack of bulk hold time studies for in-process materials, inadequate testing of labeling and packaging materials, and insufficient equipment cleaning. Additionally, the firm's change control procedures lacked due dates, resulting in numerous open change controls.
ID · eca1c26b-b995-4b88-b035-e4b5f5448a65
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.